VARIANT initiated a collaborative network with various academic teams in the aim of developing diverse gene therapy approaches for treating CRX-associated retinopathies. The consortium is using complementary disease models to generate robust proofs-of-concept of therapeutic efficiency. VARIANT's proof-of-concept studies are particularly innovative. Our therapeutic strategies and drug administration methods make our product por...
VARIANT initiated a collaborative network with various academic teams in the aim of developing diverse gene therapy approaches for treating CRX-associated retinopathies. The consortium is using complementary disease models to generate robust proofs-of-concept of therapeutic efficiency. VARIANT's proof-of-concept studies are particularly innovative. Our therapeutic strategies and drug administration methods make our product portfolio highly attractive to our future partners.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.